Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577284 | 0.91 | MCHR1 (0.43) | KDM4EMEN1KMT2ASIGMAR1ACHE | |
| SCHEMBL5577994 | 0.91 | MEN1 (0.48) | KDM4EMEN1KMT2ASIGMAR1ACHE | |
| SCHEMBL5577830 | 0.90 | MEN1 (0.49) | KDM4EMEN1KMT2ASIGMAR1ACHE | |
| SCHEMBL5577707 | 0.89 | MEN1 (0.45) | KDM4EMEN1KMT2ASIGMAR1ACHE | |
| SCHEMBL5577351 | 0.88 | MEN1 (0.54) | KDM4EMEN1KMT2ASIGMAR1ACHE | |
| SCHEMBL5577267 | 0.88 | DRD2 (0.42) | KDM4EMEN1KMT2ASIGMAR1ACHE | |
| SCHEMBL5577766 | 0.87 | APLNR (0.48) | MEN1KMT2ASIGMAR1ACHEATM | |
| SCHEMBL5577407 | 0.86 | ALDH1A1 (0.52) | KDM4ETDP1MEN1KMT2ASIGMAR1 | |
| SCHEMBL5577363 | 0.86 | LMNA (0.52) | KDM4EMEN1KMT2ASIGMAR1ACHE | |
| SCHEMBL5577935 | 0.86 | SIGMAR1 (0.48) | KDM4EMEN1KMT2ASIGMAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | KDM4E 4213/4885TDP1 3686/4885MEN1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.